clinical trial · NCT06290141
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating PolyneuropathyriliprubartPlaceboriliprubartPlaceboIVIgPlacebo
brief summary
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
started
Aug 21, 2024
primary completion
Jul 9, 2027
completion
Jan 12, 2029
last updated
Apr 21, 2026
official title
A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol